What changed in Royalty Pharma plc's latest annual report
In the year ended 31 Dec 2025, Royalty Pharma plc's revenue rose 5.1% to USD 2.38bn, from USD 2.26bn; net income fell 10.2% to USD 770.95m, from USD 858.98m; cash and cash equivalents fell 33.4% to USD 618.70m, from USD 929.03m.
Year ended 31 Dec 2025. Source: 10-K filed 11 Feb 2026, read it on SEC EDGAR.
USD 2.26bn to USD 2.38bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.26bn | 2.38bn | Up 5.1% |
| Net income | 858.98m | 770.95m | Down 10.2% |
| Total assets | 18.22bn | 19.62bn | Up 7.7% |
| Total liabilities | 7.88bn | 9.91bn | Up 25.7% |
| Long-term debt | 6.61bn | 8.57bn | Up 29.6% |
| Cash and cash equivalents | 929.03m | 618.70m | Down 33.4% |
Questions people ask
Did Royalty Pharma plc's revenue grow last year?
Revenue grew 5.1%, from USD 2.26bn to USD 2.38bn in the year ended 31 Dec 2025.
Is Royalty Pharma plc profitable?
Yes. Net income was USD 770.95m in the year ended 31 Dec 2025. The year before: USD 858.98m.
How much cash and debt does Royalty Pharma plc have?
At its latest year end (31 Dec 2025), Royalty Pharma plc reported cash and cash equivalents of USD 618.70m and long-term debt of USD 8.57bn.
Where do these numbers come from?
From Royalty Pharma plc's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Royalty Pharma plc?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%